Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8974 results

  1. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Abdominal aortic aneurysm

    Awaiting development Reference number: GID-QS10035 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  4. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  6. School-based interventions: physical and mental health and wellbeing promotion

    In development Reference number: GID-QS10070 Expected publication date: TBC

    Quality standard
    In development

  7. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  10. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-IPG10440 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  11. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 14 April 2026.

    Technology appraisal guidance
    In consultation

  12. Luspatercept for treating haemoglobin H disease [ID6714]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 16 April 2026.

    In consultation

  15. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 16 April 2026.

    Technology appraisal guidance
    In consultation